Alexandria Hammond
Stock Analyst at Wolfe Research
(2.79)
# 1,685
Out of 5,127 analysts
14
Total ratings
75%
Success rate
15.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alexandria Hammond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Downgrades: Peer Perform | n/a | $224.13 | - | 2 | Jan 8, 2026 | |
| MRK Merck & Co. | Upgrades: Outperform | $135 | $110.99 | +21.63% | 2 | Jan 8, 2026 | |
| MDGL Madrigal Pharmaceuticals | Upgrades: Neutral | $266 → $445 | $556.22 | -20.00% | 2 | Nov 3, 2025 | |
| REGN Regeneron Pharmaceuticals | Initiates: Outperform | $1,150 | $801.01 | +43.57% | 1 | Nov 15, 2024 | |
| PFE Pfizer | Initiates: Underperform | $25 | $25.29 | -1.15% | 1 | Nov 15, 2024 | |
| MRNA Moderna | Initiates: Underperform | $40 | $33.86 | +18.13% | 1 | Nov 15, 2024 | |
| LLY Eli Lilly and Company | Initiates: Outperform | $1,000 | $1,085.19 | -7.85% | 1 | Nov 15, 2024 | |
| JNJ Johnson & Johnson | Initiates: Outperform | $190 | $205.75 | -7.65% | 1 | Nov 15, 2024 | |
| GILD Gilead Sciences | Initiates: Outperform | $110 | $120.67 | -8.84% | 1 | Nov 15, 2024 | |
| BMY Bristol-Myers Squibb Company | Initiates: Peer Perform | n/a | $55.90 | - | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $186.00 | - | 1 | Nov 15, 2024 |
AbbVie
Jan 8, 2026
Downgrades: Peer Perform
Price Target: n/a
Current: $224.13
Upside: -
Merck & Co.
Jan 8, 2026
Upgrades: Outperform
Price Target: $135
Current: $110.99
Upside: +21.63%
Madrigal Pharmaceuticals
Nov 3, 2025
Upgrades: Neutral
Price Target: $266 → $445
Current: $556.22
Upside: -20.00%
Regeneron Pharmaceuticals
Nov 15, 2024
Initiates: Outperform
Price Target: $1,150
Current: $801.01
Upside: +43.57%
Pfizer
Nov 15, 2024
Initiates: Underperform
Price Target: $25
Current: $25.29
Upside: -1.15%
Moderna
Nov 15, 2024
Initiates: Underperform
Price Target: $40
Current: $33.86
Upside: +18.13%
Eli Lilly and Company
Nov 15, 2024
Initiates: Outperform
Price Target: $1,000
Current: $1,085.19
Upside: -7.85%
Johnson & Johnson
Nov 15, 2024
Initiates: Outperform
Price Target: $190
Current: $205.75
Upside: -7.65%
Gilead Sciences
Nov 15, 2024
Initiates: Outperform
Price Target: $110
Current: $120.67
Upside: -8.84%
Bristol-Myers Squibb Company
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $55.90
Upside: -
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $186.00
Upside: -